The "Zero Sugar" Deception: Seventh Circuit’s Chobani Ruling Signals a Retreat from FDA Preemption in Food Labeling Class Actions

The Collapse of the "Regulatory Compliance" Shield

For the last decade, the defense bar’s favorite weapon in food-labeling class actions has been the argument that federal regulatory approval acts as a de facto safe harbor. The logic was simple: if the FDA permits an ingredient to be excluded from the "Total Sugars" line on the Nutrition Facts panel, then a front-of-pack claim like "Zero Sugar" cannot be deceptive as a matter of law.

The Seventh Circuit just punched a hole through that shield. In reviving a proposed class action against Chobani, the court held that consumers may proceed with claims that the company’s "Zero Sugar" yogurt labeling was misleading because the product contains allulose—a rare sugar that the FDA has exempted from the "sugars" declaration on nutrition labels due to its negligible caloric impact. The decision is a sharp reminder that compliance with FDA labeling regulations does not immunize a manufacturer from state consumer protection laws when the overall impression of the label is allegedly deceptive.

Why This Matters for the Defense Bar

This ruling forces a recalibration of risk assessment for any company marketing "low sugar" or "sugar-free" products containing alternative sweeteners. Under the Nutrition Labeling and Education Act (NLEA), 21 U.S.C. § 343-1, states are generally preempted from imposing labeling requirements that differ from federal standards. However, the Seventh Circuit’s approach suggests that claims based on the net impression of a label—rather than a direct challenge to the Nutrition Facts panel itself—may survive preemption challenges.

The practical implication is significant: manufacturers can no longer rely solely on the FDA’s blessing of an ingredient’s regulatory status to shut down class actions at the pleading stage. If a plaintiff can plausibly allege that a reasonable consumer would interpret "Zero Sugar" to mean "zero impact on blood glucose" or "zero sugar alcohols," the case likely survives a Rule 12(b)(6) motion, even if the ingredient is technically not a "sugar" under FDA definitions.

The Ascertainability and Predominance Hurdle

While the Seventh Circuit revived the claims, the battle now shifts to class certification under Rule 23. The defense will almost certainly pivot to arguments regarding ascertainability and predominance. Because allulose is metabolized differently than sucrose, the defense will argue that individual issues of reliance and damages overwhelm common questions—particularly in jurisdictions that require proof of actual deception for each class member.

However, the Seventh Circuit has historically been more receptive to the "reasonable consumer" standard as a class-wide issue than some other circuits. If the court certifies a class, expect to see a surge in similar filings targeting products containing allulose, monk fruit, and stevia, where the marketing language strays into the gray area between "sugar-free" and "carbohydrate-free."

The Broader Trend: Judicial Skepticism of "Regulatory Capture" in Labeling

This decision fits into a broader pattern of federal appellate courts refusing to let FDA regulations serve as a blanket preemption for state consumer protection laws. We saw similar skepticism in the Ninth Circuit’s revival of the Natural American Spirit litigation, where the court allowed claims that "additive-free" marketing misled consumers despite the product’s compliance with certain tobacco regulations.

The message to the plaintiffs' bar is clear: the "regulatory compliance" defense is losing its potency. The message to general counsel is even clearer: your marketing team’s "Zero Sugar" claim is now a litigation target, regardless of what the FDA says about the chemistry of your sweeteners.